Search

Search Constraints

You searched for: Author/Creator Privitera, A.C.

Search Results

1. AF.51 VEDOLIZUMAB MAY BE AN EFFECTIVE OPTION FOR THE MANAGEMENT OF POSTOPERATIVE RECURRENCE OF CROHN'S DISEASE. (September 2021)

2. AF.57 SPOSAB ABP 501: A SICILIAN PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS WITH INFLAMMATORY BOWEL DISEASE TREATED WITH ADALIMUMAB BIOSIMILAR ABP 501. (September 2021)

3. OC.10.3 THE EFFECTIVENESS OF USTEKINUMAB AND VEDOLIZUMAB AS THIRD-LINE THERAPY IN PATIENTS WITH REFRACTORY CROHN'S DISEASE. (May 2022)

4. OC.12.1 SPOSIB SB2 - A SICILIAN PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS WITH INFLAMMATORY BOWEL DISEASE TREATED WITH INFLIXIMAB BIOSIMILAR SB2. (1st October 2020)

5. OC.12.3 SPOSIB SB2 – A SICILIAN PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS WITH INFLAMMATORY BOWEL DISEASE TREATED WITH INFLIXIMAB BIOSIMILAR SB2 (FLIXABI®): INTERIM ANALYSIS. (25th March 2019)

6. P.02.10 REAL-LIFE STUDY (GORE-UC) EVALUATING THE EFFECTIVENESS OF GOLIMUMAB FOR THE TREATMENT OF ULCERATIVE COLITIS: AN INTERIM ANALYSIS FROM ITALIAN GROUP FOR THE STUDY OF INFLAMMATORY BOWEL DISEASE (IG-IBD). Issue 2 (15th March 2018)

7. P.02.4 EFFECTIVENESS OF VEDOLIZUMAB ON INTESTINAL AND ARTICULAR OUTCOMES: REAL-WORLD DATA FROM THE SICILIAN NETWORK FOR INFLAMMATORY BOWEL DISEASE (SN-IBD). Issue 2 (15th March 2018)

8. P.07.1 ELDERLY PATIENTS WITH INFLAMMATORY BOWEL DISEASE (IBD) ARE LESS LIKELY TO PERSIST ON ANTI-TNF THERAPY COMPARED WITH YOUNGER PATIENTS. DATA FROM THE SICILIAN NETWORK FOR INFLAMMATORY BOWEL DISEASES (SN-IBD). (25th March 2019)

9. PC.01.2 A PROPENSITY SCORE WEIGHTED COMPARISON OF VEDOLIZUMAB AND ADALIMUMAB IN CROHN'S DISEASE: REAL-LIFE DATA FROM THE SICILIAN NETWORK FOR INFLAMMATORY BOWEL DISEASE (SN-IBD). (1st October 2020)

10. PC.01.3 SEVERE ACTIVITY OF INFLAMMATORY BOWEL DISEASE IS A RISK FACTOR FOR SEVERE COVID-19: DATA FROM THE SICILIAN NETWORK FOR INFLAMMATORY BOWEL DISEASE (SN-IBD). (September 2021)